Tech Company Financing Transactions

Ambros Therapeutics Funding Round

Ambros Therapeutics secured a $125 million Series A funding round on 12/16/2025. Investors included Enavate Sciences, RA Capital Management and Adage Capital Management.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

18575 Jamboree Road 275-S
Irvine, CA 92612
USA

Phone

(949) 508-0173

Website

www.ambrostherapeutics.com

Email Address

[email protected]

Overview

Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare metabolic bone disease that causes severe, unrelenting and frequently lasting pain following trauma to the bone or an injury. Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Joseph Hagan

        

Browse more venture capital transactions:

Prev: 12/16/2025: Leona Health venture capital transaction
Next: 12/16/2025: Curalta Foot & Ankle venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary